Novocure Ltd Ord Sh (NVCR) Stock Price, Quote & News

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic ca...

Industry: Medical Devices

Sector: Healthcare

Website: www.novocure.com

Address:

Neuhofstrasse 21, Baar, Switzerland

rvc01 Oct. 24 at 7:04 PM

$NVCR WOW! What a market!!! Everything is up...well, almost everything. LOL

0 · Reply

kamilaponce17 Oct. 24 at 3:12 PM

$NVCR — Biotech innovation with real clinical potential. $NVCR could benefit from healthcare investment trends through 2030.

0 · Reply

vicenterivas Oct. 23 at 6:46 PM

$NVCR showing some strength. Healthcare can rally too 💊

0 · Reply

Night_Owl_Biotech Oct. 23 at 6:19 PM

$SNDX FY2026 & 10-year revenue multiple versus all commercial-stage oncology focused bios with market caps over $1.0B. SNDX's cumulative 10-year analyst revenue estimate excludes the highest revenue forecast for all 10-years. Using actual analyst consensus, SNDX trades at 0.12X 10-year revenues. Valuations use intra-day share prices on 10/23/2025 $IBRX trades at the 2nd lowest multiple. However, we understand IBRX needs future clinical wins to realize those estimates. We are not 100% certain $PGEN belongs in this peer group. Any suggestions would be welcome. $JAZZ multiples use enterprise value. $NVCR also appears a value using analyst estimates & multiples versus peers. We understand ST users express doubts on whether analyst estimates are credible in light of lung related sales to date. This is not investment advice.

3 · Reply

scotofool Oct. 21 at 6:29 PM

$NVCR blokes $NVCR bandooglizing wee investors, fakey results to authoritys, proper cock-up, target 7

1 · Reply

buylowandwait Oct. 20 at 6:14 PM

$NVCR It is in management's hand to show that multi-indication franchise actually means sth from revenue point of view ! The Metis P3 trial results have been available for more than 1 years, but we still don't know if FDA filing was done ! Patiently waiting for Q3 results to understand what management has done for the company. This is my worst performer for the year, and I hope next two years, the dog turns around, and it truly has the potential.

2 · Reply

GordonGecko_was_THE_MAN Oct. 20 at 3:48 PM

$NVCR Additional (post-doc) Panova-3 analysis from ESMO (yesterday). My read: If patients actually wear the TTF arrays, they do much better (no surprise)! Data for the fist 3 months of usage shows: Wear TTF arrays >50% of the time, mOS = 17.1 months Wear TTF arrays < 50% of the time, mOS = 13.8 months Interesting to note: 166 patients wore arrays > 50% of time in 1st 3 months, while 107 patients wore the device <50% of the time. Remember target compliance = wearing arrays 75%. So more than a 1/3 of the patients in the TTF arm of the trial barely wore the arrays at all, and the trial still hit its endpoint.

4 · Reply

GoBigRed19 Oct. 18 at 3:13 AM

$NVCR

0 · Reply

BB_88_ Oct. 17 at 7:41 PM

$NVCR 13.8 should crack shortly

0 · Reply

BB_88_ Oct. 17 at 7:26 PM

$NVCR bullish long term but took a 13.9 short in to close

1 · Reply

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum

Oct 15, 2025, 7:00 AM EDT - 10 days ago

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Oct 1, 2025, 7:00 AM EDT - 24 days ago

Novocure to Report Third Quarter 2025 Financial Results

Sep 29, 2025, 4:30 PM EDT - 26 days ago

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Sep 15, 2025, 7:00 AM EDT - 5 weeks ago

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sep 10, 2025, 5:53 PM EDT - 6 weeks ago

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Novocure Announces Upcoming Investor Events

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Aug 20, 2025, 7:00 AM EDT - 2 months ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Jul 30, 2025, 12:47 AM EDT - 3 months ago

NovoCure's Wearable Oncology Edge And Compelling Valuation

Jul 28, 2025, 6:52 AM EDT - 3 months ago

Top 3 Health Care Stocks That May Explode In July

HCA MOH

Jul 25, 2025, 4:49 PM EDT - 3 months ago

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

Jul 24, 2025, 7:00 AM EDT - 3 months ago

Novocure Reports Second Quarter 2025 Financial Results

Jul 1, 2025, 7:00 AM EDT - 4 months ago

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Jun 30, 2025, 7:00 AM EDT - 4 months ago

Novocure to Report Second Quarter 2025 Financial Results

Jun 2, 2025, 2:05 PM EDT - 5 months ago

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

May 31, 2025, 3:08 PM EDT - 5 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

ZLAB

May 31, 2025, 8:00 AM EDT - 5 months ago

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 24, 2025, 3:12 AM EDT - 5 months ago

NovoCure: Loading Up On Growth Catalysts

Apr 24, 2025, 12:39 PM EDT - 6 months ago

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

Apr 24, 2025, 10:34 AM EDT - 6 months ago

NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 7:00 AM EDT - 6 months ago

Novocure Reports First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 6 months ago

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 7:09 AM EDT - 6 months ago

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Apr 1, 2025, 7:00 AM EDT - 7 months ago

Novocure to Report First Quarter 2025 Financial Results

Mar 4, 2025, 7:00 AM EST - 8 months ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Feb 28, 2025, 1:10 PM EST - 8 months ago

NovoCure Q4 2024 Earnings: Strong And Growing Pipeline

Feb 28, 2025, 5:17 AM EST - 8 months ago

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth

Feb 27, 2025, 9:09 AM EST - 8 months ago

NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript

Feb 27, 2025, 7:00 AM EST - 8 months ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Jan 22, 2025, 4:00 AM EST - 9 months ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Jan 13, 2025, 7:00 AM EST - 10 months ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 3, 2025, 7:00 AM EST - 10 months ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 9:59 PM EST - 11 months ago

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer

Dec 2, 2024, 1:10 PM EST - 11 months ago

Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields

Dec 2, 2024, 10:12 AM EST - 11 months ago

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

Dec 2, 2024, 7:17 AM EST - 11 months ago

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Dec 2, 2024, 7:02 AM EST - 11 months ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

ZLAB

Dec 2, 2024, 7:00 AM EST - 11 months ago

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Nov 27, 2024, 7:00 AM EST - 11 months ago

Novocure to Participate in Upcoming Investor Conferences

Nov 21, 2024, 7:05 AM EST - 1 year ago

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Nov 21, 2024, 7:00 AM EST - 1 year ago

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Oct 30, 2024, 11:53 AM EDT - 1 year ago

NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript

Oct 30, 2024, 7:02 AM EDT - 1 year ago

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Novocure Reports Third Quarter 2024 Financial Results

Oct 16, 2024, 11:00 AM EDT - 1 year ago

NovoCure: There Is Still More Upside

Oct 16, 2024, 7:28 AM EDT - 1 year ago

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients

Oct 15, 2024, 4:43 PM EDT - 1 year ago

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Novocure to Report Third Quarter 2024 Financial Results

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

rvc01 Oct. 24 at 7:04 PM

$NVCR WOW! What a market!!! Everything is up...well, almost everything. LOL

0 · Reply

kamilaponce17 Oct. 24 at 3:12 PM

$NVCR — Biotech innovation with real clinical potential. $NVCR could benefit from healthcare investment trends through 2030.

0 · Reply

vicenterivas Oct. 23 at 6:46 PM

$NVCR showing some strength. Healthcare can rally too 💊

0 · Reply

Night_Owl_Biotech Oct. 23 at 6:19 PM

3 · Reply

scotofool Oct. 21 at 6:29 PM

$NVCR blokes $NVCR bandooglizing wee investors, fakey results to authoritys, proper cock-up, target 7

1 · Reply

buylowandwait Oct. 20 at 6:14 PM

2 · Reply

GordonGecko_was_THE_MAN Oct. 20 at 3:48 PM

4 · Reply

GoBigRed19 Oct. 18 at 3:13 AM

$NVCR

0 · Reply

BB_88_ Oct. 17 at 7:41 PM

$NVCR 13.8 should crack shortly

0 · Reply

BB_88_ Oct. 17 at 7:26 PM

$NVCR bullish long term but took a 13.9 short in to close

1 · Reply

scotofool Oct. 16 at 3:17 AM

$NVCR @AdamCrush wanker, no blokes wants this proper trash 25 or 15, defective harming, stop spreadings falsies, Roche me arse

0 · Reply

NeuroRad Oct. 15 at 6:48 PM

$NVCR stars possibly aligning for this stock with positive catalysts in 2026 in combination with fed easing. I keep coming back to CEO 1 million open market purchase.

0 · Reply

AdamCrush Oct. 15 at 2:12 PM

$NVCR acquisition at $25 by EU Pharma co Roche

2 · Reply

Night_Owl_Biotech Oct. 14 at 1:54 PM

Change in share price of all commercial-stage oncology focused bios with market caps north of $300MM since last weeks close (using share prices this morning as of 9:40 AM). The XBI is off 2% where most in this peer group are off much more. $ZYME is clearly the biggest winner the last 5 trading days $ONC $GERN $NVCR SNDX & $AUTL are off the most in the peer group For information purposes only. This is not investment advice.

0 · Reply

Tdorsey1776 Oct. 13 at 5:30 PM

$NVCR $SRRK $QURE $TMDX I've had a pretty good run in bios this year and decided it was time to once again make random (not just year end for tax purposes) donations to St. Jude's to share the wealth. Please remember there are kids suffering and families struggling to cope with cancer. St. Jude's makes a difference. 5K donation made, more to come. Good fortune to all. https://www.stjude.org/donate/donate-to-st-jude.html?sc_icid=home-btn-donate-now

1 · Reply

BiotechBonesaw Oct. 13 at 1:01 PM

$JFBR $NUKK $PPBT $SEDG $NVCR God for the peace deal & hostage return ☮️

1 · Reply

mohernx Oct. 11 at 6:54 PM

$NVCR

0 · Reply

mohernx Oct. 11 at 6:53 PM

$NVCR Dancing baby is on a buying mode again. Listening to the song "How deep is your Love" 10 nish is sweet

0 · Reply

scotofool Oct. 9 at 6:18 PM

$NVCR blokes me trustys big coverups bad safety leaky soons, wait investors learn hiding proper cock-up, target 7

0 · Reply

Tdorsey1776 Oct. 8 at 11:52 PM

$NVCR Keep on Truckin

0 · Reply

Stonkapedia Oct. 8 at 10:33 AM

$NVCR POS 💩

0 · Reply

nikitatrades Oct. 7 at 10:24 AM

$NVCR is transitioning to a multi-indication co! Building on its $600M+ GBM biz, it expects 3 new launches by end of 2026: lung cancer (Optune Lua), pancreatic cancer (filed Aug '25), & brain mets. Goal: diversify revenue & path to profitability. 🚀 #Oncology #Investing Lung cancer launch is challenging (device in a drug world), but $NVCR is learning & adapting. The REAL excitement is pancreatic cancer—CEO's "favorite child." PMA submitted, approval expected mid-2026. PANOVA-4 Phase II data due Q1 2026 could be a catalyst. 🧠 #Biotech Strong financial position: $900M+ cash, convert debt to be paid off. Existing GBM biz is cash flow positive, growing mid-single digits. With 4 products soon, SG&A leverage is built—top-line growth should drive path to profitability. Trading at a discount to fundamentals. 💰 #NVCR

0 · Reply

Market Cap	1.56B
Revenue (ttm)	605.22M
Net Income (ttm)	-168.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27.86%
Debt to Equity Ratio	0.28

Volume	1,061,500
Avg Vol	1,522,070
Day's Range	N/A - N/A
Shares Out	111.80M
Stochastic %K	51%
Beta	0.75
Analysts	Strong Sell
Price Target	$27.19